research Retinoic Acid Is Not Involved in Fluconazole-Induced Alopecia: Evaluation in a Human Cohort and Rat Model
Retinoic acid is not linked to hair loss from fluconazole use.
Search
for
Sort by
Research
960-990 / 1000+ results research BH06: Clinical trial of combination therapy with oral hydroxychloroquine and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia
research Evaluation of Pericardial Effusions in Alopecia Patients on Low-Dose Oral Minoxidil Therapy
Low-dose oral minoxidil does not increase pericardial effusions in alopecia patients.
research SAT-369 Marine-Lenhart Syndrome: Case Report
Combining medication and minimally invasive techniques can effectively manage Marine-Lenhart syndrome.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Study on inhibitory effect of Urtica laetevirens Maxim. extract on 5α-reductase
Urtica laetevirens extract significantly reduces 5α-reductase activity.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research DOSE DEPENDENT INHIBITORY EFFECT OF LAGENARIA SICERARIA FRUIT POWDER ON FSH AND LH HORMONES IN MALE WISTAR RATS
High doses of Lagenaria siceraria fruit powder lower FSH and LH hormone levels in male rats.
research The Development of BL 7660 as an Anti‐Acne Agent
BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
research Efficacy of Topical Latanoprost Versus Topical Minoxidil In the Treatment of Alopecia Areata: Clinical and Dermoscopic Study
Latanoprost is more effective than minoxidil for treating alopecia areata.
research A comparative study of Aldactone® and Diane® in the treatment of hirsutism
Aldactone was more effective in reducing hair growth in women with hirsutism than Diane, despite having less impact on hormone levels.
research Successful treatment of non-pruritus, excessive hair shedding and scales in a cat due to Demodex gatoi with fluralaner topical spot-on
Fluralaner topical spot-on successfully treated a cat's hair shedding and scales caused by Demodex gatoi.
research withdrawn
Dutasteride works better than finasteride for hair growth with similar side effects.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
research Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling
Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Spironolactone in combination drug therapy for unresponsive hirsutism
Combination drug therapy is effective for hirsutism that doesn't improve with just one medication.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Preliminary toxicity profile of arotinoids SMR-2 and SMR-6 in male B6D2F1 mice*1
SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
research Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University
Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
research Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.